SNOA · Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals, Inc. entered into an underwriting agreement with Dawson James Securities, Inc. to facilitate a public offering of its securities. The offering, priced at $1.35 per unit, consisted of shares of common stock, pre-funded warrants, and common warrants. The closing occurred on April 27 and 28, 2026, with the underwriter fully exercising the over-allotment option. This resulted in the issuance of 1,650,716 shares of common stock, 1,312,247 pre-funded warrants, and 3,407,404 common warrants. The common warrants are exercisable at $1.35 per share and expire five years from the date of issuance. The Company expects to receive net proceeds of approximately $3.5 million after deducting underwriting discounts and offering expenses. The agreement includes standard terms such as a 7.5% underwriting fee, a 1% non-accountable expense allowance, and the issuance of an underwriter's warrant. Additionally, the Company and its executive officers and directors agreed to a 90-day lock-up period restricting the sale of company securities. The net proceeds are intended for general corporate purposes, including working capital.